Replies to post #41296 on Ariad Pharmaceuticals Inc fka ARIA

[binchey]

I will only do if i manage to sell my position with 250,000$ profit

[grandma_of_jbraika]

Any attorney out there considering suing the FDA, SEC or others over the FDA's actions and the SEC's failure to investigate re: Ariad's Iclusig (we'll have a look at Novartis) can reach me. I will be your lead plaintiff. I will bring you others in a class action.

To me, the evidence doesn't point at Ariad management, it points at the FDA, the SEC and possibly Novartis.

Everyone is quick to sue Ariad. The aforementioned trio is where this mess should be blamed.

That Times article is quite telling. 32 experts, experts in CML are up in arms. 530 patients that were at deaths doorstep, 14 die. 14 die, not 530. It is sad 14 people die. 265 would have died for sure without the drug, the other half would have to survive a tricky BM transplant, if they find a donor.

The facts - Novartis is ruthless in protecting its franchises, around the world. Tasigna has similar SAE's just now being revealed. Novartis bribes, cheats, lies at every level around the world, then pay a fine and move on.

- No one can say in reality what causes the SAEs, genetics, the CML disease itself, the advanced stages of the disease, the patient age and condition, a combination of these and other factors. There isn't even agreement that the SAEs are even SAEs. Without Iclusig, cause of SAE namely death is certain, it's CML, and the other medicines tried and failed

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=94968258

When one analyst questioned the wisdom of publicly taking issue with US regulators, Ariad chief scientific officer Timothy P. Clackson said, “We felt obligated to, in a very careful way, explain our understanding” of the clinical data because of fears the FDA “created a lot of confusion and questions” among doctors and patients.

The FDA "created a lot of confusion and questions” among doctors and patients by intentionally not following the standard SAE-reporting criteria with an agenda. Ariad felt obligated to stay with the stand. Consequently, the FDA came down hard on Ariad.